GlassScriptPhysician profile
Thomas G Vance
NPI 1649654385
$11,864.42
in general payments reported to CMS, 2019-2025
56 companies · $2,612 in 2025
The $2,612 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,984 · 2022: $2,012 · 2023: $2,179 · 2024: $3,077 · 2025: $2,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,593 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,593.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,585.77 | 2021-2025 | |
| Glaxosmithkline, LLC. | $731.73 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $726.61 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $678.48 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Pfizer INC. | $548.17 | 2022-2025 | |
| Novo Nordisk INC | $527.88 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $521.21 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $349.33 | 2022-2025 | Caplyta |
| Amgen INC. | $346.01 | 2021-2025 | Evenity, Prolia, Krystexxa |
| Janssen Biotech, INC. | $275.10 | 2021-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $260.36 | 2021-2025 | |
| Eko Health, INC. | $225.00 | 2024-2025 | |
| Lundbeck LLC | $196.11 | 2021-2025 | Vyepti |
| Aimmune Therapeutics, INC. | $183.65 | 2024-2025 | Zenpep |
| Abbott Laboratories | $181.49 | 2023-2025 | Freestyle Libre 3, Freestyle Insulinx |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.